AstraZeneca divestment of Movantik to RedHill Biopharma completed Medical Dialogues Bureau4 April 2020 11:00 AM ISTUK: AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada,...
AstraZeneca Lokelma recommended for approval in EU for patients with hyperkalaemia on stable haemodialysis Medical Dialogues Bureau31 March 2020 1:05 PM ISTLokelma is a highly selective, oral potassium-removing agent currently approved in the US, EU, Canada, Hong Kong, China, Russia, and Japan for the...
Cipla gets USFDA final nod for Esomeprazole ANDA for Oral Suspension Medical Dialogues Bureau27 March 2020 12:51 PM ISTCipla's Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is an AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical's ...
AstraZeneca gets orphan drug designation for pancreatic cancer drug Lynparza Medical Dialogues Bureau24 March 2020 11:30 AM ISTUK: AstraZeneca has announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of...
AstraZeneca's Phase III CASPIAN trial final analysis shows Imfinzi confirmed survival benefit for small cell lung cancer patients Medical Dialogues Bureau21 March 2020 9:00 AM ISTImfinzi confirmed a sustained overall survival benefit in the final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell...
AstraZeneca Pharma India gets DCGI nod for Calquence-Acalabrutinib 100mg capsules Medical Dialogues Bureau14 March 2020 12:03 PM ISTAcalabrutinib 100mg capsules are indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).
AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 9:30 AM ISTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not...
AstraZeneca to sublicense global rights to Movantik Medical Dialogues Bureau28 Feb 2020 9:00 AM ISTMovantik is a once-daily oral PAMORA approved by the US Food and Drug Administration for the treatment of OIC in adult patients with chronic...
AstraZeneca 2020 revenue rises, sales growth to take coronavirus hit Medical Dialogues Bureau18 Feb 2020 10:30 AM ISTAstraZeneca said the guidance assumed an unfavourable impact from China lasting up to a few months as a result of the outbreak, which has killed over...
Cipla arm inks pact for anti-psychotic drug Quetiapine Farhat Nasim11 Feb 2020 12:15 PM ISTNew Delhi: Cipla Medpro South Africa (Pty) Ltd, a wholly-owned subsidiary of Cipla Ltd, India, has recently concluded an exclusive agreement securing...
Sun Pharma reports Rs 6923.40 crore total expenses in Q3 Farhat Nasim7 Feb 2020 4:43 PM ISTNew Delhi: Drug major Sun Pharmaceutical Industries on Thursday reported a 26.43 per cent decline in its consolidated net profit to Rs 913.52 crore...
Drugmajors slash prices by 53pc for China bulk-buy program eligibility Medical Dialogues Bureau20 Jan 2020 10:00 AM ISTBeijing: Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest...
